Baidu
map

Stroke:控制血压是卒中预防的正确目标吗?

2015-05-10 李志行 译 MedSci原创

尽管针对高血压的药物治疗大有裨益,但其无法通过预防和延迟高血压的方法来保持理想健康进而从中获益。研究方法:总计26875名年龄在45岁以上的黑人和白人参与者接受有关突发卒中事件的评估和随访。1、根据评估突发卒中和收缩压(SBP)之间的关联将其分类为正常(<120 mm Hg)、高血压前期(120–139 mm Hg)、高血压第一阶段(140–159 mm Hg)和高血压第二阶段(160 mm

点击查看原图

尽管针对高血压的药物治疗大有裨益,但其无法通过预防和延迟高血压的方法来保持理想健康进而从中获益。

研究方法:
总计26875名年龄在45岁以上的黑人和白人参与者接受有关突发卒中事件的评估和随访。1、根据评估突发卒中和收缩压(SBP)之间的关联将其分类为正常(<120 mm Hg)、高血压前期(120–139 mm Hg)、高血压第一阶段(140–159 mm Hg)和高血压第二阶段(160 mm Hg+)。2、根据高血压药物的分级,分为0、1、2、3或更高。

研究结果:
在为期6.3年的随访过程中有823次卒中事件发生。接近一半(46%)的参与者为得到较好治疗(SBP<140 mm Hg)的高血压患者。就血压而言,对血压正常的参与者所需抗高血压药物每额外增加一级发生卒中的风险也随之增加,风险比(HR)为 1.33;95%的可信区间为1.16到1.52。对高血压前期的患者HR为1.15;95%的可信区间为1.05到1.26。对高血压第一阶段的患者HR为1.22;95%的可信区间为1.06到1.39。一位接受较好治疗(SBP<120 mm Hg)的高血压患者,处于抗高血压药物3+级,相比较没有接受任何治疗的高血压第一阶段患者,具有稍高的卒中风险(HR, 2.48 vs HR=2.19)。

单纯通过药物治疗来保持血压正常的状态具有深刻的影响,正如队列中接近一半的普通参与者按照指南的要求(SBP<140 mm Hg)接受相关治疗,但是其风险等级并没有达到正常人水平。即使接受良好治疗,通过预防和延迟高血压也只是存在一定的潜在收益。

原始出处:
George Howard, Maciej Banach, Mary Cushman, David C. Goff, Virginia J. Howard, Daniel T. Lackland, Jim McVay, James F. Meschia, Paul Muntner, Suzanne Oparil, Melanie Rightmyer, and Herman A. Taylor
Is Blood Pressure Control for Stroke Prevention the Correct Goal?The Lost Opportunity of Preventing Hypertension
Stroke 2015; first published on May 7 2015 as doi:10.1161/STROKEAHA.115.009128

本文是MedSci原创编译整理,欢迎转载!转载请注明来源并附原文链接。谢谢!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1988319, encodeId=33f2198831984, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Thu Sep 17 22:49:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33512, encodeId=70d83351235, content=看了, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47091635965, createdName=化蝶, createdTime=Sun Jul 26 16:02:00 CST 2015, time=2015-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23445, encodeId=45512344560, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 21:23:00 CST 2015, time=2015-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447383, encodeId=4ca5144e383de, content=<a href='/topic/show?id=35cc36081e2' target=_blank style='color:#2F92EE;'>#卒中预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36081, encryptionId=35cc36081e2, topicName=卒中预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd925339785, createdName=陈吴1236, createdTime=Tue May 12 11:49:00 CST 2015, time=2015-05-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1988319, encodeId=33f2198831984, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Thu Sep 17 22:49:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33512, encodeId=70d83351235, content=看了, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47091635965, createdName=化蝶, createdTime=Sun Jul 26 16:02:00 CST 2015, time=2015-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23445, encodeId=45512344560, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 21:23:00 CST 2015, time=2015-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447383, encodeId=4ca5144e383de, content=<a href='/topic/show?id=35cc36081e2' target=_blank style='color:#2F92EE;'>#卒中预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36081, encryptionId=35cc36081e2, topicName=卒中预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd925339785, createdName=陈吴1236, createdTime=Tue May 12 11:49:00 CST 2015, time=2015-05-12, status=1, ipAttribution=)]
    2015-07-26 化蝶

    看了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1988319, encodeId=33f2198831984, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Thu Sep 17 22:49:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33512, encodeId=70d83351235, content=看了, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47091635965, createdName=化蝶, createdTime=Sun Jul 26 16:02:00 CST 2015, time=2015-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23445, encodeId=45512344560, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 21:23:00 CST 2015, time=2015-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447383, encodeId=4ca5144e383de, content=<a href='/topic/show?id=35cc36081e2' target=_blank style='color:#2F92EE;'>#卒中预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36081, encryptionId=35cc36081e2, topicName=卒中预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd925339785, createdName=陈吴1236, createdTime=Tue May 12 11:49:00 CST 2015, time=2015-05-12, status=1, ipAttribution=)]
    2015-05-13 huaxipanxing

    看看

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1988319, encodeId=33f2198831984, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Thu Sep 17 22:49:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33512, encodeId=70d83351235, content=看了, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47091635965, createdName=化蝶, createdTime=Sun Jul 26 16:02:00 CST 2015, time=2015-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23445, encodeId=45512344560, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 21:23:00 CST 2015, time=2015-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447383, encodeId=4ca5144e383de, content=<a href='/topic/show?id=35cc36081e2' target=_blank style='color:#2F92EE;'>#卒中预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36081, encryptionId=35cc36081e2, topicName=卒中预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd925339785, createdName=陈吴1236, createdTime=Tue May 12 11:49:00 CST 2015, time=2015-05-12, status=1, ipAttribution=)]

相关资讯

Stroke:高血压患者服用非甾体抗炎药(NSAIDs)增加卒中风险

已经有研究调查了脑血管事件发生风险与高危患者使用非甾体类抗炎药(NSAIDs)之间的关系,但研究很有限。该研究调查了使用选择性和非选择性非甾体类抗炎药短期内(30天内)对高血压患者的缺血性和出血性卒中风险的影响。 使用台湾国家健康保险研究数据库进行了一项病例交叉研究。该研究确定了来自2010年的1653患有卒中的高血压患者。调整了潜在混杂因素后利用条件逻辑评估了使用NSAIDs对卒中的影响。

JAMA Pediatr:高钾膳食有助青春期降低血压

科学界一直认为摄入过多量的饮食性的钠导致高血压和心血管疾病风险升高。在发达国家中,每日钠摄取估计在3500mg,而美国膳食指南推荐2-50岁的健康人的每日钠摄取量不超过2300mg。几个临床试验的meta分析表明增高的钾摄入量降低了高血压成年人的血压。然而基于人群的研究并没有发现这一联系。在较年轻人群中的钾对血压影响的数据仍是有限的和不一致的。早些时候的几个研究表明当钾离子摄入量相对较高而钠离子摄

高血压、使用呋塞米,竟与原发性甲旁亢相关?

一项新研究发现,很多老年白人女性的原发性甲状旁腺机能亢进的风险明显升高,与高血压及使用呋塞米密切相关。 来自美国的研究者评估了护士健康研究中75600例女护士的数据,从1986年随访至2008年,基线时无原发性甲状旁腺机能亢进,目的是确定高血压病史、使用某些抗高血压药物是否可升高原发性甲状旁腺机能亢进的风险。 在高血压人群中,在超过70万人-年的随访中,共计出现222例原发性甲状旁腺机能亢进,

Cell:血管紧张素受体——瞄准人类健康的隐形杀手

每三个美国人中就有一人罹患高血压,这一人类健康的隐形杀手可以导致冠心病、心力衰竭和中风等疾病。利用一种先进的X-射线分析技术,由来自美国、德国的科学家组成的一个研究小组,揭示出了人体中最重要的血压调控因子——血管紧张素受体AT1R的分子结构。他们的研究结果发表在4月23日的《细胞》(Cell)杂志上。南加州大学Dornsife文理学院首席研究员及教授Vadim Cherezov说,这项研究工作有可

Baidu
map
Baidu
map
Baidu
map